L

Latigo Biotherapeutics

Clinical-stage biotech developing Nav1.8 inhibitors

Overview

Latigo Biotherapeutics develops non-opioid pain medicines by discovering and advancing small-molecule drugs, focusing on Nav1.8 channels in peripheral sensory neurons. By blocking Nav1.8, their therapies aim to stop pain at its source, reducing opioid-related risks like addiction and dizziness. The company uses a genetics-informed discovery engine with AI, machine learning, and structure-based design; LTG-001 targets acute pain and LTG-305 targets chronic pain, both in clinical stages. Its differentiated approach centers on genetically validated pain pathways, strong funding, and experienced leadership, with the goal of delivering safe, effective non-opioid analgesics that address pain at its source.

Work here?Claim your company

About Latigo Biotherapeutics

Simplify's Rating
Not yet rated

We're working on gathering enough insights on this company, check back soon!

Industries

BiotechnologyHealthcare

Company Size

51-200

Company Stage

IPO

Headquarters

Thousand Oaks, CA

Founded

2018

Get referred to Latigo Biotherapeutics

See people who can refer or advise you

Funding

Total Funding

$682.4M

Above

Industry Average

Funded Over

3 Rounds

IPO funding comparison data is currently unavailable. We're working to provide this information soon!
IPO Funding Comparison Coming Soon

Benefits

  • Hybrid Work Options

Stock Price

Growth & Insights

6 month growth

14%

1 year growth

38%

2 year growth

80%

Recently Posted Jobs

Sign up to get curated job recommendations

Latigo Biotherapeutics is Hiring for 17 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs